1Paqcker M,Poole-Wilson PA,Armstrong PW,et al.Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor,lisinopril,on morbidity and mortality in chronic heart failure.ATLAS Study Group.Circulation,1999,100(23):2312
2Jackson G,Gibbs CR,Davies MK,et al.ABC of heart failure pathophysiology.BMJ,2000,320:167-170
3Gibbs CR,Davies MK,Lip GYH.ABC of heart failure management.BMJ,2000,320:495-498
4Lonn E,Mckelvie.Drug treatment in heart failure.BMJ,2000,320:1188-1192
5McMurray J,Pfeffer MA.New therapeutic options in congestive heart failure:Part Ⅰ.Circulation,2002,105:2099-2106
6Consensus Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure:results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).N Engl J Med,1987,316:1429-1435
7Cohn JN,Johnson G.A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic heart failure.N Engl J Med,1991,325:303-310
8Pfeffer MA,Braunwald E.On behalf of SAVE investigators effect of captopril on morbidity in patients with left ventricular dysfunction after myocardial infarction:results of the survival of ventricular enlargment trial.N Engl J Med,1992,327:669
9The SOLVD Investigators.Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction.N Engl J Med,1992,327:685
10Lee SC,Stevens TL,Sandberg SM,et al.The potential of brain natriuretic peptide in risk atratification of patients with congestive heart failure[].Journalism Assn of Community College.2001